Virtual Library

Start Your Search

Hiromitsu Ota

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-79 - Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients with Brain Metastases (ID 13141)

      12:00 - 13:30  |  Author(s): Hiromitsu Ota

      • Abstract
      • Slides


      The brain is a common site of metastatic disease in patients with non-small cell lung cancer (NSCLC). Approximately 30–50% of patients will develop brain metastases during the course of treatment. Several immune check-point inhibitors (ICIs) have shown efficacy against non–small-cell lung cancers (NSCLCs) and approved in second line setting. However, regarding ICIs intracerebral efficacy and tolerability in NSCLC patients with active brain metastases (BMs) remains unkown.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We reviewed the medical charts of 49 patients with advanced NSCLC treated with ICIs between January 2016 and March 2018. The intracranial activity of ICIs in patients with brain metastases was assessed by brain magnetic resonance imaging (MRI) using RECIST v. 1.1 criteria. The primary endpoint was intracerebral objective response rate (IORR). Secondary endpoints included intracerebral control rate, intracerebral and general progression-free survival (PFS), overall survival (OS) and tolerance.

      4c3880bb027f159e801041b1021e88e8 Result

      Ten NSCLC patients with BMs were identified. The median age of patients was 61 years (range 44–80 years) and the majority of patients were male (n = 9; 90%). All patients were pretreated with stereotaxic radiosurgery (n = 7) or whole brain radiation therapy (n = 3). All but one patients received prior systemic treatment for NSCLC. Three patients received two prior lines of systemic therapy. Two patients were treated with pembrolizumab. Median follow-up was 5.7 (95% CI: 2.7–8.4) months. IORR and extracerebral response rate were, respectively, 0% (95% CI: 0–25.9%) and 20% (95% CI: 2.5–55.6%). Intracerebral control rate was 60% (95% CI: 26.2–87.8%). Median intracerebral and general PFS lasted 1.8 (95% CI: 0.9–7.1) and 2.8 (95% CI: 1.8–4.6) months, respectively. Median OS was 8.9 (95% CI: 4.9–not reached) months. No neurological adverse events occurred.

      8eea62084ca7e541d918e823422bd82e Conclusion

      ICIs might have the efficacy and favorable safety profile in NSCLC patients with BMs.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.